# Novel Dose Escalation to Predict Treatment With Hydroxyurea

> **NCT02042222** · EARLY_PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 70 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT02042222
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-07-31
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02042222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02042222, "Novel Dose Escalation to Predict Treatment With Hydroxyurea". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02042222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*